|Bid||0.0000 x 21500|
|Ask||0.0000 x 800|
|Day's Range||2.4900 - 2.6800|
|52 Week Range||2.4900 - 9.9500|
|Beta (3Y Monthly)||1.61|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.71|
BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -42.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
—New drug application for once-daily oral BCX7353 for prophylaxis of hereditary angioedema attacks on-track for submission in Q4 2019— —Data from ongoing Phase 1 trial of oral.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees options to purchase an aggregate of 42,000 shares of BioCryst common stock on July 31, 2019 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $3.17 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RESEARCH TRIANGLE PARK, N.C., July 23, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2019 financial.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees options to purchase an aggregate of 33,000 shares of BioCryst common stock on June 30, 2019, and granted Megan Sniecinski, the company’s new chief business officer, the option to purchase an aggregate of 500,000 shares of BioCryst common stock on July 1, 2019, in each case as inducements material to each employee entering into employment with BioCryst. The June 30, 2019 options have an exercise price of $3.79 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date, and the July 1, 2019 options have an exercise price of $3.71 per share, which is equal to the closing price of BioCryst common stock on the grant date.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced the appointment of Megan Sniecinski as chief business officer. Ms. Sniecinski joins BioCryst from PTC Therapeutics, where she served as senior vice president of business operations and program management since June 2017. Over nearly five years at PTC, Ms. Sniecinski played a key role in supporting the diversified growth of PTC’s rare disease pipeline and transformation into a global, fully-integrated biopharmaceutical company.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has begun enrollment of a Phase 1 trial of BCX9930, an oral Factor D inhibitor discovered and developed by BioCryst, for the treatment of complement-mediated diseases. “An oral Factor D inhibitor would meet a significant unmet medical need for patients with many complement-mediated diseases. The preclinical profile of BCX9930 showed high potency, excellent specificity for Factor D, complete suppression of complement-mediated hemolysis after oral dosing, and a wide safety margin, so we look forward to seeing the clinical results from this Phase 1 trial,” said Dr. William Sheridan, chief medical officer of BioCryst.
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has experienced […]
RESEARCH TRIANGLE PARK, N.C., May 31, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies 2019 Healthcare.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...
One Triangle drug-maker is feeling confident following a successful Phase III trial – despite some less confident investors pulling the stock down nearly 50 percent.
BioCryst announced Tuesday that a Phase 3 study dubbed APeX-2, which is evaluating once-daily, oral BCX7353 — a selective inhibitor of plasma kallikrein — in preventing hereditary angioedema, or HAE, attacks, met the primary endpoint for both the 110mg and 150mg dose levels. The primary efficacy endpoint is the rate of investigator-confirmed angioedema attacks over 24 weeks of study drug administration. The 110mg dose of BCX7353 reduced the HAE attack rate by 30 percent compared to placebo and the 150mg dose reduced the attack rate by 44 percent.
Fifty percent of patients receiving 150 mg BCX7353 in APeX-2 had a ≥ 70 percent reduction in their HAE attack rate compared to baseline, compared to 15 percent of placebo patients (p=0.002). In patients on the 150 mg dose with a baseline attack rate of
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
RESEARCH TRIANGLE PARK, N.C., May 10, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America Merrill Lynch.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers. In the trial, galidesivir was generally safe and well tolerated. This placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of escalating doses of galidesivir in four single-dose cohorts of 5mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kg, with a total of 24 volunteers receiving galidesivir by IV infusion. Drug exposures (Cmax and AUC) at the highest dose were 20,500 ng/mL and 44,600 hr.ng/mL, similar to or greater than drug exposures needed in nonclinical galidesivir treatment experiments in Marburg virus disease and Yellow Fever.